BACKGROUND: The relationship between stage of chronic kidney disease (CKD) and incident heart failure (HF) remains unclear. METHODS: Of the 5,795 community-dwelling adults ≥65 years in the Cardiovascular Health Study, 5,450 were free of prevalent HF and had baseline estimated glomerular filtration rate (eGFR: ml/min/1.73 m(2)) data. Of these, 898 (16%) had CKD 3A (eGFR 45-59 ml/min/1.73 m(2)) and 242 (4%) had CKD stage ≥3B (eGFR <45 ml/min/1.73 m(2)). Data on baseline proteinuria were not available and 4,310 (79%) individuals with eGFR ≥60 ml/min/1.73 m(2) were considered to have no CKD. Propensity scores estimated separately for CKD 3A and ≥3B were used to assemble two cohorts of 1,714 (857 pairs with CKD 3A and no CKD) and 557 participants (148 CKD ≥3B and 409 no CKD), respectively, balanced on 50 baseline characteristics. RESULTS: During 13 years of follow-up, centrally-adjudicated incident HF occurred in 19, 24 and 38% of pre-match participants without CKD (reference), with CKD 3A [unadjusted hazard ratio (HR) 1.40; 95% confidence interval (CI) 1.20-1.63; p < 0.001] and with CKD ≥3B (HR 3.37; 95% CI 2.71-4.18; p < 0.001), respectively. In contrast, among matched participants, incident HF occurred in 23 and 23% of those with CKD 3A and no CKD, respectively (HR 1.03; 95% CI 0.85-1.26; p = 0.746), and 36 and 28% of those with CKD ≥3B and no CKD, respectively (HR 1.44; 95% CI 1.04-2.00; p = 0.027). CONCLUSIONS: Among community-dwelling older adults, CKD is a marker of incident HF regardless of stage; however, CKD ≥3B, not CKD 3A, has a modest independent association with incident HF.
BACKGROUND: The relationship between stage of chronic kidney disease (CKD) and incident heart failure (HF) remains unclear. METHODS: Of the 5,795 community-dwelling adults ≥65 years in the Cardiovascular Health Study, 5,450 were free of prevalent HF and had baseline estimated glomerular filtration rate (eGFR: ml/min/1.73 m(2)) data. Of these, 898 (16%) had CKD 3A (eGFR 45-59 ml/min/1.73 m(2)) and 242 (4%) had CKD stage ≥3B (eGFR <45 ml/min/1.73 m(2)). Data on baseline proteinuria were not available and 4,310 (79%) individuals with eGFR ≥60 ml/min/1.73 m(2) were considered to have no CKD. Propensity scores estimated separately for CKD 3A and ≥3B were used to assemble two cohorts of 1,714 (857 pairs with CKD 3A and no CKD) and 557 participants (148 CKD ≥3B and 409 no CKD), respectively, balanced on 50 baseline characteristics. RESULTS: During 13 years of follow-up, centrally-adjudicated incident HF occurred in 19, 24 and 38% of pre-match participants without CKD (reference), with CKD 3A [unadjusted hazard ratio (HR) 1.40; 95% confidence interval (CI) 1.20-1.63; p < 0.001] and with CKD ≥3B (HR 3.37; 95% CI 2.71-4.18; p < 0.001), respectively. In contrast, among matched participants, incident HF occurred in 23 and 23% of those with CKD 3A and no CKD, respectively (HR 1.03; 95% CI 0.85-1.26; p = 0.746), and 36 and 28% of those with CKD ≥3B and no CKD, respectively (HR 1.44; 95% CI 1.04-2.00; p = 0.027). CONCLUSIONS: Among community-dwelling older adults, CKD is a marker of incident HF regardless of stage; however, CKD ≥3B, not CKD 3A, has a modest independent association with incident HF.
Authors: Anand S Iyer; Mustafa I Ahmed; Gerasimos S Filippatos; O James Ekundayo; Inmaculada B Aban; Thomas E Love; Navin C Nanda; George L Bakris; Gregg C Fonarow; Wilbert S Aronow; Ali Ahmed Journal: J Am Soc Hypertens Date: 2010 Jan-Feb
Authors: Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy Journal: Circulation Date: 2009-03-26 Impact factor: 29.690
Authors: Yuqing Chen; Michael S Lipkowitz; Rany M Salem; Maple M Fung; Vibha Bhatnagar; Manjula Mahata; Caroline M Nievergelt; Fangwen Rao; Sushil K Mahata; Nicholas J Schork; Pamela J Hicks; Donald W Bowden; Barry I Freedman; Victoria H Brophy; Daniel T O'Connor Journal: Am J Nephrol Date: 2010-05-19 Impact factor: 3.754
Authors: Christine Ritchie; O James Ekundayo; Maureen Muchimba; Ruth C Campbell; Stuart J Frank; Bo Liu; Inmaculada B Aban; Ali Ahmed Journal: Int J Cardiol Date: 2009-05-29 Impact factor: 4.164
Authors: O James Ekundayo; Richard M Allman; Paul W Sanders; Inmaculada Aban; Thomas E Love; Donna Arnett; Ali Ahmed Journal: Hypertension Date: 2009-02-02 Impact factor: 10.190
Authors: O James Ekundayo; Virginia J Howard; Monika M Safford; Leslie A McClure; Donna Arnett; Richard M Allman; George Howard; Ali Ahmed Journal: Am J Cardiol Date: 2009-05-14 Impact factor: 2.778
Authors: O James Ekundayo; Louis J Dell'Italia; Paul W Sanders; Donna Arnett; Inmaculada Aban; Thomas E Love; Gerasimos Filippatos; Stefan D Anker; Donald M Lloyd-Jones; George Bakris; Marjan Mujib; Ali Ahmed Journal: Int J Cardiol Date: 2009-02-06 Impact factor: 4.164
Authors: C Barrett Bowling; Bertram Pitt; Mustafa I Ahmed; Inmaculada B Aban; Paul W Sanders; Marjan Mujib; Ruth C Campbell; Thomas E Love; Wilbert S Aronow; Richard M Allman; George L Bakris; Ali Ahmed Journal: Circ Heart Fail Date: 2010-01-26 Impact factor: 8.790
Authors: Kanan Patel; Xuemei Sui; Yan Zhang; Gregg C Fonarow; Inmaculada B Aban; Cynthia J Brown; Vera Bittner; Dalane W Kitzman; Richard M Allman; Maciej Banach; Wilbert S Aronow; Stefan D Anker; Steven N Blair; Ali Ahmed Journal: Int J Cardiol Date: 2013-02-04 Impact factor: 4.164
Authors: Ali Ahmed; Michael W Rich; Michael Zile; Paul W Sanders; Kanan Patel; Yan Zhang; Inmaculada B Aban; Thomas E Love; Gregg C Fonarow; Wilbert S Aronow; Richard M Allman Journal: Am J Med Date: 2013-02 Impact factor: 4.965